Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN
Browse
PeptideMethods · Semaglutide · https://peptidemethods.com/peptides/semaglutide · printed 2026-06-03
GLP-1 agonist

Semaglutide

Prescription23 resources9 min read · evidence-led · not medical advice
Evidence depth88/100
Source recency75% <3yr
Safety clarity92/100
How we score these
Last updated: 2026-05-29

Reported benefits and downsides

Each item is tagged with the kind of evidence behind it and a strength dial. Read the dial first, the claim second. How we grade evidence strength.

Reported benefits

  • Substantial weight loss in obesityRCT
    Strong evidence

    STEP-1 (2021): mean 14.9% body-weight reduction at 68 weeks with 2.4 mg weekly, vs 2.4% on placebo.

  • Reduced cardiovascular events in obesity without diabetesRCT
    Strong evidence

    SELECT (2023): 20% reduction in major adverse cardiovascular events (HR 0.80, P<0.001) in adults with established CV disease and BMI ≥27.

  • Improved glycaemic control in type-2 diabetesRCT
    Strong evidence

    SUSTAIN programme: substantial HbA1c reductions across SUSTAIN-1 through SUSTAIN-7 versus placebo and active comparators.

  • Reduced kidney-failure progression in T2D + CKDRCT
    Strong evidence

    FLOW (2024): 24% reduction in the composite kidney-failure endpoint in type-2 diabetes plus chronic kidney disease.

  • Reduced appetite and prolonged satietyEstablished
    Strong evidence

    Central GLP-1 receptor action in the hypothalamus and brainstem; characterised mechanism, not just self-report.

Reported downsides

  • Gastrointestinal side effectsCommon AE
    Strong evidence

    Nausea, vomiting, diarrhoea, constipation. Dose-dependent and usually mitigated by slow titration but the most common reason people stop.

  • Weight regain after discontinuationEstablished
    Strong evidence

    STEP-4 extension: most of the weight comes back when participants switch from semaglutide to placebo at week 20.

  • Thyroid C-cell tumour boxed warningBoxed warning
    Moderate evidence

    Rodent data drove the FDA boxed warning. Human relevance is uncertain, but a personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication.

  • Pancreatitis and gallbladder eventsRare AE
    Moderate evidence

    Acute pancreatitis is rare; gallbladder events (cholelithiasis, cholecystitis) are more common with rapid weight loss.

  • Cost and accessPractical
    Strong evidence

    Expensive without insurance coverage; reimbursement varies country to country and indication to indication.

Where it works, where it doesn't

Where it works

  • Type-2 diabetes, especially with elevated cardiovascular risk (guideline-recommended add-on)
  • Chronic weight management at BMI ≥ 30, or ≥ 27 with comorbidities, per Wegovy labelling
  • Cardiovascular-event reduction in overweight or obese adults without diabetes (SELECT, 2023)
  • Patients who can tolerate slow dose-titration through the early GI side-effect window

Where it doesn't

  • Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome (boxed-warning contraindication)
  • Goals built around a defined stop date (STEP-4 showed substantial weight regain after discontinuation)
  • Pregnancy and pregnancy-planning windows (contraindicated; washout advised before conception)
  • Cost-sensitive scenarios without insurance coverage; the branded products remain expensive

Where the literature comes from

An editorial estimate of the kinds of evidence available for Semaglutide, not just what this page cites. Peptide research is rarely RCT-heavy, so the mix matters as much as the volume.

  • Human RCTs60%
  • Regulatory / agency22%
  • Mechanism / pharmacology10%
  • Systematic reviews5%
  • Case reports / off-label3%

How we estimate this mix: see methodology.

History at a glance

Key moments in the Semaglutide story, from first synthesis through today.

  1. 2008

    First synthesis at Novo Nordisk

    Discovery

    Modified GLP-1 analogue with reversible albumin binding for once-weekly dosing.

  2. 2016

    SUSTAIN-6: cardiovascular safety signal in T2D

    Trial

    Marso et al. report reduced major adverse cardiovascular events in type-2 diabetes (NEJM).

  3. 2017

    FDA approval of Ozempic

    Approval

    First semaglutide product authorised, for type-2 diabetes; weekly subcutaneous dosing.

  4. 2019

    FDA approval of Rybelsus

    Approval

    First oral GLP-1 agonist; once-daily tablet formulation of semaglutide.

  5. 2021

    STEP-1 published; FDA approval of Wegovy

    Approval

    Wilding et al. report 14.9% mean weight loss at 68 weeks; Wegovy approved for chronic weight management.

  6. 2022

    US shortage begins

    Regulatory

    Demand outpaces supply; FDA lists semaglutide in shortage, permitting compounded versions under 503A/503B.

  7. 2023

    SELECT: 20% MACE reduction in obesity without diabetes

    Trial

    Lincoff et al. (NEJM) report the first cardiovascular-outcome benefit for a weight-loss medication in non-diabetic obesity.

  8. 2024

    FLOW: kidney-outcomes benefit in T2D + CKD

    Trial

    Perkovic et al. (NEJM) report a 24% reduction in the composite kidney-failure endpoint.

  9. 2024

    US shortage resolved; compounding wind-down

    Regulatory

    FDA declares the semaglutide shortage resolved; enforcement discretion for large-scale compounding begins to wind down.

What we know

Semaglutide is the most-studied compound in our library by a wide margin, and the only one with multiple large cardiovascular-outcome trials behind it. It belongs to the GLP-1 receptor agonist class and is marketed by Novo Nordisk under three brand names: Ozempic (once-weekly subcutaneous, for type-2 diabetes), Rybelsus (once-daily oral, also for type-2 diabetes), and Wegovy (once-weekly subcutaneous at higher doses, for chronic weight management). All three carry European Medicines Agency authorisation valid across the EU and EEA, and equivalent authorisations from the MHRA in the UK and the FDA in the US. None is sold over the counter anywhere.

In type-2 diabetes, the SUSTAIN programme established semaglutide as an HbA1c-lowering and weight-reducing add-on, and SUSTAIN-6 (Marso et al., NEJM 2016) found a statistically significant reduction in major adverse cardiovascular events in patients with type-2 diabetes at elevated cardiovascular risk. That CV-outcomes signal moved semaglutide from "a good glycaemic agent" to a guideline-recommended option where cardiovascular comorbidity exists. The trial data are summarised in the EMA Ozempic EPAR and the FDA approval letter linked below.

In obesity, the STEP programme produced the modern weight-loss numbers most people now associate with the class. STEP-1 (Wilding et al., NEJM 2021) reported a mean body-weight reduction of 14.9% at 68 weeks with semaglutide 2.4 mg plus lifestyle intervention, versus 2.4% with placebo plus the same lifestyle intervention. That was the largest mean weight loss seen in a non-surgical obesity trial up to that point. STEP-3, STEP-4 and STEP-8 added detail on diet co-intervention, discontinuation, and head-to-head comparisons against liraglutide. STEP-4 in particular is worth knowing about, because it tested what happens when people who have lost weight on semaglutide switch to placebo. The answer is that most of the weight comes back.

In 2023, the SELECT trial (Lincoff et al., NEJM 2023) reported a 20% reduction in major adverse cardiovascular events (a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) in adults with overweight or obesity and pre-existing cardiovascular disease but no diabetes (hazard ratio 0.80, P<0.001). This was the first time a weight-loss medication had shown a hard cardiovascular benefit in the obesity-without-diabetes population, and it is the trial that drove most of the 2024–2026 expansion of GLP-1 prescribing into cardiovascular-preventive practice.

In the EU and EEA, all three brand presentations are authorised centrally by the EMA and dispensed on prescription: Ozempic and Rybelsus for type-2 diabetes, Wegovy for chronic weight management and cardiovascular-risk reduction. In the UK, the MHRA authorises the same presentations. In the US, the FDA approved Ozempic in 2017, Rybelsus in 2019, and Wegovy in 2021, all prescription-only. Country-specific detail (including reimbursement and supply notes) lives on our regulation pages at /regulation/[country]/semaglutide.

A note on the 2022–2024 shortage years and compounding: when semaglutide was on the FDA drug-shortage list, US compounding pharmacies could legally prepare versions of it under sections 503A and 503B of the FD&C Act. The FDA later declared the shortage resolved and began winding down enforcement discretion for large-scale compounding. As of 2026, the branded products are the authorised route in the US; compounded semaglutide outside narrow exceptions sits outside that authorisation. Across the EU and UK, compounded semaglutide was never the default route, and EMA and national regulators have warned repeatedly about counterfeit Ozempic and Wegovy pens entering supply chains.

There is also a parallel grey market: vials labelled "semaglutide, for research use only" sold by online research-chemical vendors. That label does not make the product safe, legal for human use, or pharmaceutically equivalent to Ozempic/Wegovy/Rybelsus. Independent purity testing of these products has been mixed at best, and the regulatory framework in every country we cover treats them as unauthorised medicines, not as a parallel-but-cheaper version of the branded drug. We cover this honestly because pretending it doesn't exist is unhelpful, but our position is consistent: the only credible way to use semaglutide is through a prescribing clinician and a regulated pharmacy.

This page is for educational and journalistic purposes. We do not advise on starting, stopping, dosing, or sourcing semaglutide. Those conversations belong with a clinician who knows your history. Use the country pages below to see how semaglutide is regulated where you live, the FAQ to surface the most-asked questions, and the source list to read the primary trial and regulatory documents in full.

How it works

Semaglutide is a structural analogue of native GLP-1 (glucagon-like peptide-1, a hormone your gut releases after you eat that tells the pancreas to release insulin and the brain that you're full). It binds the GLP-1 receptor (the protein on cells that GLP-1 normally activates). The molecule is chemically modified, including reversible albumin binding (where the drug temporarily clings to a protein in the blood so the body clears it more slowly), so its half-life stretches to about a week. That is what makes once-weekly subcutaneous dosing, and once-daily oral dosing of Rybelsus, practical. Three pharmacological effects matter clinically: enhanced glucose-dependent insulin secretion (insulin is released only when blood glucose is already elevated, which is why the hypoglycaemia, low-blood-sugar, risk on its own is low), suppression of glucagon (the hormone that raises blood sugar by telling the liver to release stored glucose), and slowed gastric emptying (food leaves the stomach more slowly, so you feel full longer). The weight-loss effect is driven primarily centrally: GLP-1 receptors in the hypothalamus and brainstem (the brain regions that regulate appetite and satiety) reduce hunger and prolong fullness, and that same central action accounts for most of the gastrointestinal side-effect profile.

Where it acts in the body

  1. Hypothalamus and brainstemActivates central GLP-1 receptors to suppress appetite and prolong satiety. The dominant driver of weight loss.
  2. PancreasEnhances glucose-dependent insulin secretion and suppresses glucagon, lowering blood glucose without driving hypoglycaemia on its own.
  3. StomachSlows gastric emptying, prolonging the feeling of fullness after meals and contributing to GI side effects.
  4. Cardiovascular systemHard cardiovascular-outcome benefit shown in SUSTAIN-6 (T2D) and SELECT (obesity without diabetes); mechanism includes weight loss, improved glycaemia, and direct vascular effects.
  5. KidneysFLOW (2024) reports reduced progression of kidney failure in type-2 diabetes plus chronic kidney disease.

Safety

The dominant adverse-event signal across the SUSTAIN (diabetes) and STEP (weight) trial programmes is gastrointestinal: nausea, vomiting, diarrhoea and constipation, all dose-dependent and largely mitigated by slow titration. Less common but clinically meaningful events include acute pancreatitis (rare), gallbladder-related events such as cholelithiasis and cholecystitis (more common with rapid weight loss), and worsening of diabetic retinopathy seen in SUSTAIN-6, attributed in part to rapid HbA1c lowering. The US label carries a boxed warning regarding thyroid C-cell tumours observed in rodents; the human relevance is uncertain, but a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome is a contraindication. Hypoglycaemia risk is low on monotherapy but increases when semaglutide is combined with insulin or sulfonylureas. Pregnancy is a contraindication, and a washout period is advised before conception.

Practical considerations

How the literature has dosed Semaglutide, what it costs where it's authorised, how to spot a counterfeit product, and the customs reality. We report. We do not prescribe.

Dosing & administration

Once-weekly subcutaneous injection for Ozempic and Wegovy; once-daily oral tablet for Rybelsus. Approved doses depend on indication and are in each product's label.

ContextRangeReference
SUSTAIN programme (type-2 diabetes)0.5 or 1.0 mg weekly SC; later trials reached 2.0 mgMarso 2016 (SUSTAIN-6) and the broader SUSTAIN-1 through -10 series
STEP-1, STEP-4 (chronic weight management)Titrated to 2.4 mg weekly SC over 16 weeksWilding 2021; Rubino 2021
SELECT (CV-event reduction in obesity)Titrated to 2.4 mg weekly SCLincoff 2023
PIONEER programme (oral semaglutide)3, 7 or 14 mg once daily PO, taken with up to 120 ml water on an empty stomachEMA Rybelsus EPAR

All trial dosing was clinician-supervised with structured titration to manage gastrointestinal side effects. Real-world starting and target doses depend on indication, weight, comorbidities and tolerability. We report what the literature used. We do not recommend a dose. That conversation belongs with a prescribing clinician.

Cost & access

Branded products are expensive and reimbursement varies sharply by country and by indication. Figures below are approximate 2026 ballparks; verify with the regulator, the manufacturer's patient-assistance programme, or your local pharmacy.

United States
Ozempic ≈ $1,000–1,350 monthly cash list. Wegovy similar. Patient-assistance programmes from Novo Nordisk may reduce the price for eligible patients. Insurance coverage depends on indication (T2D coverage broader than obesity) and plan.
United Kingdom
NHS prescriptions available for type-2 diabetes; Wegovy is available within NICE criteria for chronic weight management. Private prescriptions typically £200–400+ monthly depending on dose and pharmacy.
Denmark, Sweden, Norway
Reimbursed for type-2 diabetes within national criteria. Obesity-indication reimbursement is more restrictive and may require specialist referral.
Germany, Netherlands
Type-2 diabetes is reimbursed under standard criteria. Obesity-indication coverage is patchier and often paid out-of-pocket.

Quality verification

Branded Ozempic, Wegovy and Rybelsus go through regulated pharmaceutical supply chains. Online 'semaglutide for research use only' from research-chemical vendors is a different product, not held to those standards, and the subject of frequent counterfeit warnings from EMA, MHRA and FDA.

What legitimate products show

  • Original branded packaging with intact tamper-evidence and a holographic security label where used
  • A valid prescription dispensed through a licensed pharmacy
  • Batch number and expiry that match the manufacturer's lookup

Counterfeit red flags

  • Pens or vials sold online without a prescription
  • Loose vials labelled 'semaglutide, for research use only'
  • Compounded versions sold outside the FDA's narrow continuing-use exceptions, post the 2024 shortage resolution
  • Packaging in a language different from the listed country of origin
  • Prices substantially below pharmacy norms in the same region

Travel & customs

Holders of a valid prescription for Ozempic, Wegovy or Rybelsus can generally travel with the medication across our coverage area. Carry the original packaging, a copy of the prescription, and a doctor's letter if travelling outside Europe. Customs may detain unverified or compounded versions, and personal importation of unapproved versions is generally not permitted.

In the conversation

Credentialed experts and podcasters who have covered Semaglutide on the record. We link the original source, attribute by full name, and disclose any conflict of interest. We do not paraphrase as if it were our work.

  1. Spencer Nadolsky, DOTier 2PodcastSigma Nutrition Radio #582: GLP-1 Agonists — Side Effects, Management and Diet (host: Danny Lennon)Oct 2025

    Nadolsky covers GLP-1 mechanism [05:24], efficacy and weight-loss outcomes [07:55], side-effect management [16:53], muscle-mass concerns during weight loss [22:57], and nutritional considerations on therapy [28:09]. Semaglutide, tirzepatide (he labels it a 'twincretin' for dual GLP-1/GIP receptor action) and liraglutide are the drugs named. The episode's framing per the show notes: GLP-1 receptor agonists have 'emerged as a groundbreaking tool in obesity treatment,' delivering weight loss 'previously seen only with surgical interventions.'

    Conflict of interest: Operates Spencer Nadolsky obesity-medicine clinic and the LiftRx platform; commercial interest in obesity treatment.

    Listen→ at 00:05:24

  2. Eric Topol, MDTier 2NewsletterGround Truths Substack: The Peptide CrazeJul 2025

    Topol sets GLP-1 receptor agonists apart from the rest of the 'peptide craze' he critiques. He writes that the GLP-1 class are 'one of, if not the most rigorously studied class of peptides ever, with many large, placebo-controlled, randomized trials' and that 'the adverse events of GLP-1 drugs have been extensively characterized from large randomized trials with placebo controls.' He flags growing off-label use and microdosing as moving outside that evidence base. Useful as the rigorous-medicine framing semaglutide deserves.

    Read→

  3. Andrew Huberman, PhDTier 3VideoThe goop podcast with Gwyneth Paltrow: Andrew Huberman on Protein Myths, Peptides, and the Science of Feeling Better

    Huberman walks Paltrow through the GLP-1 story: how the class originated when 'some nerdy biologist' isolated the peptide from a Gila monster, why early diabetes-dose GLP-1 didn't drive much weight loss (two-to-four-fold increases), and how Ozempic and Mounjaro pushed circulating levels 'a thousand-fold' to produce weight loss but also muscle loss. He flags retatrutide ('GLP-3', Eli Lilly) as the next step — a milder agonist that also raises glucagon and GIP, with 'lower side effect profile' and 'up to a third of body weight' loss reported, plus 'some muscle-sparing effect.' On supply: 'I do recommend that people avoid black market and gray market sources because they can be less than pure.'

    Conflict of interest: Tier 3 reflects the goop platform context (history of medical-claim controversies) and the absence of explicit primary-source citations; Huberman discusses mechanism and trial design accurately but does not name individual RCTs. Huberman's commercial relationships include the Momentous supplement line and a long track record of supplement-company sponsorships.

    Watch→

  4. Spencer Nadolsky, DO and Karl Nadolsky, MDTier 2PodcastDocs Who Lift: GLP-1 Maintenance — What Happens When You Lower Your Dose, Switch Medications, or Stop EntirelyMay 2026

    The Nadolsky brothers break down two new randomised controlled trials on what happens when GLP-1 patients lower the dose, switch medications, or stop entirely. Reported findings they cite: roughly 25–30% of patients on maximum tirzepatide doses failed to maintain 85% of their weight loss; about 17% maintained weight off medication across multiple studies; fewer than 5% of their own clinic patients on maximum tolerated doses experienced significant regain. They cover Surmount-4, Surmount-Maintain, Attain-Maintain and Surmount-5 by name, and flag oral GLP-1 alternatives as a maintenance route. Closing note on supply: unapproved research peptides like retatrutide pose safety concerns without FDA approval.

    Conflict of interest: Spencer Nadolsky runs an obesity-medicine clinic; Karl Nadolsky is in endocrinology practice. Both have commercial interests in obesity treatment.

    Listen→

  5. Spencer Nadolsky, DO; Karl Nadolsky, MD; Dr. Henning Langer (guest)Tier 2PodcastDocs Who Lift: Do GLP-1 Medicines Actually Cause Muscle Loss? New Research With Dr. Henning Langer (Charité Berlin)Apr 2026

    Spencer and Karl Nadolsky host Dr. Henning Langer (Charité Berlin) on his newly published combined rodent + human work on GLP-1 effects on skeletal muscle. Reported takeaways they discuss: the STEP-1 figure of ~40% lean-mass loss may overstate the muscle-specific picture because DEXA conflates muscle with glycogen, liver mass and water; most incretin trials show ~25% lean-mass loss; mice on semaglutide actually improved treadmill endurance despite appearing visually weaker; relative strength and endurance held while absolute muscle force only modestly declined. Practical takeaway: resistance training plus adequate protein intake reduces muscle loss by roughly 50% regardless of the pharmacology.

    Conflict of interest: Spencer Nadolsky's obesity-medicine clinic and Karl Nadolsky's endocrinology practice both carry obesity-treatment commercial interests. Dr. Langer is an academic researcher at Charité.

    Listen→

  6. Spencer Nadolsky, DO; Karl Nadolsky, MD; Dr. Grant Tinsley; Dr. Stephen Heymsfield (guest)Tier 2PodcastDocs Who Lift: Bimagrumab and Semaglutide — The BELIEVE Trial Results With Dr. Stephen Heymsfield (Pennington Biomedical Research Center)Mar 2026

    The Nadolsky brothers and Dr. Grant Tinsley host Dr. Stephen Heymsfield (Pennington Biomedical Research Center, body-composition heavyweight) on the BELIEVE trial — a nine-group study he led that combined bimagrumab (an activin-receptor blocker that promotes muscle growth) with semaglutide. Headline finding they discuss: 'over 90 percent of weight lost in the combination group was pure fat.' Bimagrumab-only patients lost 7% of weight entirely as fat without reducing food intake; visceral adipose tissue nearly disappeared in antibody-treated groups; grip strength and physical-activity measures improved. They also trace the drug's development path through Novartis, Versanis and Eli Lilly. Notable LDL-cholesterol findings flagged for follow-up.

    Conflict of interest: Spencer and Karl Nadolsky run obesity-medicine practices. Dr. Heymsfield is an academic at Pennington Biomedical Research Center with a long history of body-composition research relationships across the obesity-pharma industry.

    Listen→

  7. Ralph DeFronzo, MD (guest, hosted by Peter Attia, MD)Tier 2PodcastThe Peter Attia Drive #337: Insulin resistance masterclass — the full body impact of metabolic dysfunction and prevention, diagnosis, and treatmentFeb 2025

    DeFronzo, the academic clinician who introduced metformin into US type-2 diabetes treatment, gives an 80-minute masterclass with Attia. Two segments matter for the semaglutide page: 'GLP-1 agonists, the Qatar study, and rethinking diabetes treatment' at [1:31:30] and 'How GLP-1-induced weight loss affects muscle mass, the benefits and risks of myostatin inhibitors' at [1:51:30]. DeFronzo's framing across the episode positions GLP-1s as a paradigm shift in diabetes management against the traditional metformin-first approach.

    Conflict of interest: DeFronzo is academic (UT Health San Antonio) with a long history of pharma research and advisory relationships across the T2D drug industry, including the GLP-1 class. Attia's commercial relationships include Early Medical, Momentous and content businesses.

    Listen→ at 01:31:30

  8. Peter Attia, MDTier 2PodcastThe Peter Attia Drive #320 / AMA #64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro)Oct 2024

    Attia covers Ozempic and Wegovy (semaglutide), Mounjaro (tirzepatide), and the development-pipeline triple agonist retatrutide. Headline practical takeaway: 'If you're taking these drugs, really, really pay attention to your protein consumption and your resistance training' — preserving lean mass during weight loss is the central clinical concern. Episode also covers weight regain after discontinuation, the broader benefits beyond weight loss (sleep apnoea, immune function, cancer risk, kidney disease, cardiovascular health) and the remaining unknowns: cyclic use, rebound appetite, paediatric effects, long-term safety.

    Conflict of interest: Operates Early Medical longevity clinic with GLP-1 prescribing line; Momentous supplement-line affiliation; content and book businesses.

    Listen→

  9. David Allison, PhD (guest, hosted by Peter Attia, MD)Tier 2PodcastThe Peter Attia Drive #314: Rethinking nutrition science — the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standardsAug 2024

    Allison (Dean, Indiana University School of Public Health; obesity-research methodologist) discusses GLP-1s in three dimensions with Attia: risk-benefit framing for obesity treatment, motivations driving rapid uptake, and the case for considering GLP-1 use by athletes as performance enhancement. Two of his framings worth keeping: on nutrition science generally, 'We're talking often about subtle effects that may not be that clinically reliable and meaningful. And so the really big effect seems to be how many calories do you eat?' On the public-health response, the field needs 'a radically different public health paradigm.' He pushes for higher research-rigor and integrity standards on obesity drugs specifically.

    Conflict of interest: Allison is academic; no notable commercial COI flagged. Attia's relationships include Early Medical, Momentous and content businesses.

    Listen→

  10. Peter Attia, MDTier 2PodcastThe Peter Attia Drive #279 / AMA #53: Metabolic health & pharmacologic interventions — SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statinsNov 2023

    Attia compares the major pharmacologic levers in metabolic health: SGLT-2 inhibitors, metformin, GLP-1 agonists and statins. GLP-1 framing here is the methodical clinical view — how they sit alongside (and against) metformin and SGLT-2 inhibitors for type-2 diabetes and weight management. On statins specifically he notes: 'It is worth noting, and this is a very important question, that it does not appear that the effect of statins on insulin resistance is a function of lipids being lowered' — included because the episode arc keeps coming back to insulin-resistance management as the substrate for the GLP-1 conversation.

    Conflict of interest: Operates Early Medical longevity clinic with GLP-1 prescribing line; Momentous supplement-line affiliation; content and book businesses.

    Listen→

  11. Danny Lennon, MSc (host)Tier 3PodcastSigma Nutrition Premium SNP15: AMA — Semaglutide, 'Carni-nutrients', Sweating From Caffeine, & MoreMar 2023

    Sigma Nutrition Premium AMA. Semaglutide segment opens at [00:11:52] with the framing question 'Game-changer? Weight regain?' Lennon's review of the early evidence picture and his framing of the practical clinical-evidence-vs-hype line. Most of the segment content sits behind the Sigma Premium paywall and is not independently verifiable from the public show notes — Tier 3 reflects the paywall and the conversational AMA format rather than primary-source citation.

    Conflict of interest: Danny Lennon is an academic-credentialed (MSc) science communicator; no notable commercial COI flagged.

    Listen→ at 00:11:52

  12. Peter Attia, MDTier 2PodcastThe Peter Attia Drive #246 / AMA #45: Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agentMar 2023

    Attia's first dedicated AMA on GLP-1 weight-loss drugs. His central concern, stated verbatim: 'The thing that concerns me the most with these drugs… is this drive towards sarcopenia.' He frames the trade-off between substantial weight-loss efficacy and lean-mass loss, increased resting heart rate, potential thyroid-cancer risk, weight regain after discontinuation, and significant cost. Outlines patient-selection criteria rather than endorsing widespread use. Notable because his stance hardens visibly between this 2023 AMA and the later AMA #64 (2024): the muscle-loss concern remains central but the broader benefits side of the picture has expanded.

    Conflict of interest: Operates Early Medical longevity clinic with GLP-1 prescribing line; Momentous supplement-line affiliation; content and book businesses.

    Listen→

  13. Priya Sumithran, MD PhD (guest, hosted by Alan Flanagan, PhD and Danny Lennon, MSc)Tier 2PodcastSigma Nutrition Radio #460: Body Fat Regulation, Pros & Cons of Weight Loss Interventions, and GLP-1 Receptor AgonistsNov 2022

    Sumithran (endocrinologist and obesity researcher, University of Melbourne) explains the physiology that makes weight regain after dieting almost inevitable: 'Diet-induced weight loss is followed by a number of hormonal changes that encourage weight regain.' Episode covers GLP-1 receptor agonists (including semaglutide) as obesity treatment options against that hormonal backdrop, alongside non-weight-centric strategies and patient-selection considerations. Useful as the mechanistic framing for why a chronic-therapy model fits the disease better than a 'lose-the-weight-and-stop' model.

    Conflict of interest: Sumithran is academic with research relationships across the obesity-pharma industry, including past advisory work; hosts Flanagan and Lennon are independent science communicators.

    Listen→

Vetted vendors

Vendor reviews launching Q3 2026

We order from vendors ourselves, send samples to an independent lab, and publish what we find, including the ones that get it wrong. Semaglutide-specific vendor reviews will live here when the testing programme is live. Until then, please assume any online seller is unverified.

Latest updates

  1. 24 May 2024

    FLOW trial: semaglutide slows CKD progression in type-2 diabetes

    The NEJM publication of FLOW (Perkovic et al., 2024) reported a 24% reduction in the composite kidney-failure endpoint in type-2 diabetes plus chronic kidney disease. Adds a kidney-outcomes pillar to the existing CV-outcomes evidence.

  2. 11 Nov 2023

    SELECT published: 20% MACE reduction in obesity without diabetes

    Lincoff et al. report the first hard cardiovascular-outcome benefit for a weight-loss medication in adults with overweight or obesity and pre-existing cardiovascular disease but no diabetes.

Frequently asked

Is semaglutide prescription-only?

Yes. Across the EU, EEA, UK and US, semaglutide (sold as Ozempic, Rybelsus, and Wegovy) is a prescription-only medicine. It is not available over the counter and is not classified as a supplement anywhere we cover.

How much weight loss can I expect on semaglutide?

The STEP-1 trial (Wilding et al., NEJM 2021) reported a mean body-weight reduction of 14.9% at 68 weeks on semaglutide 2.4 mg plus lifestyle intervention, versus 2.4% on placebo plus the same lifestyle. The word "mean" is doing a lot of work there: individual response varies widely, some people lose substantially more and some substantially less, and these are trial-condition results with structured lifestyle support, not the unaided real-world picture.

What happens when you stop semaglutide?

STEP-4 is the relevant trial: participants who had lost weight on semaglutide for 20 weeks were randomised to continue or to switch to placebo. The placebo group regained a large share of the weight they had lost. The clinical implication is that semaglutide treats obesity the way an antihypertensive treats high blood pressure. Discontinuation tends to be followed by recurrence.

Is semaglutide safe?

It has been studied in tens of thousands of patients across the SUSTAIN, STEP, SELECT and FLOW programmes and has a well-characterised adverse-event profile, primarily gastrointestinal, with smaller signals for pancreatitis, gallbladder events, and (in type-2 diabetes) diabetic-retinopathy worsening on rapid HbA1c reduction. The US label carries a boxed warning regarding thyroid C-cell tumours observed in rodents; a personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication. As with any prescription medicine, safety depends on individual context. That conversation belongs with a clinician.

Can I buy 'research grade' semaglutide online?

Vials labelled "semaglutide, for research use only" exist on the grey market. That label does not legalise human use, does not guarantee pharmaceutical-grade purity, and does not put the product inside any of the regulatory frameworks (EMA, MHRA, FDA) that the branded products operate under. Regulators across our coverage area treat these products as unauthorised medicines. PeptideMethods does not facilitate the sale of any peptide and does not endorse this route.

Is compounded semaglutide still legal in the US?

Generally no, as of 2026. While semaglutide was on the FDA drug-shortage list (roughly 2022 through early 2024), US compounding pharmacies could legally prepare versions of it under sections 503A and 503B. The FDA has since declared the shortage resolved and has been winding down enforcement discretion for large-scale compounding. Narrow exceptions for individual patients remain in specific clinical circumstances. The current authoritative position is on the FDA's compounding policy page, which we link below.

Glossary

Quick definitions for the technical terms used on this page. Hover any term in the body text and most browsers show the same definition; this section is the canonical reference.

GLP-1
Glucagon-like peptide-1. A hormone the gut releases after meals that prompts insulin release and signals fullness to the brain.
GLP-1 receptor agonist
A drug class that activates the GLP-1 receptor, mimicking native GLP-1's effects.
HbA1c
A blood test reflecting average glucose over the previous 8–12 weeks. The standard glycaemic control marker in diabetes.
MACE
Major adverse cardiovascular events. Composite endpoint typically including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
Medullary thyroid carcinoma (MTC)
A rare thyroid cancer arising from parafollicular C cells. A boxed-warning contraindication for semaglutide.
MEN-2
Multiple endocrine neoplasia type 2. A genetic syndrome that predisposes carriers to medullary thyroid carcinoma.
Pancreatitis
Inflammation of the pancreas. A rare but clinically meaningful adverse event flagged for GLP-1 agonists.
RCT
Randomised controlled trial. The standard for evaluating whether a treatment causes a measured effect.
T2D
Type-2 diabetes. The most common form of diabetes, driven primarily by insulin resistance.
Titration
Gradual dose escalation over weeks. Used with semaglutide to reduce gastrointestinal side effects.

Recent coverage

All blog posts →

Three most recent articles from the daily editorial pipeline that mention Semaglutide.

PeptideMethods · This page is educational, not medical advice. Verified 2026-05-29 · © 2026 Digital Compass Group Ltd · peptidemethods.com